thakur quickly uncovered disturbing problems with the data required by the f.d.a.o prove the effectiveness of ranbaxy drugs. >> the data is important because the f.d.a., or other agencies globally, look at that information to give ranbaxy authorization to sell that drug. >> reporter: that it works, that it's safe. >> that's right. we started getting into the files, and lo and behold, we find none of it exists in the first place. >> reporter: what did that mean? >> it means we've gotten approvals from the f.d.a. to sell drugs that were based on no data, or data that was fraudulent. >> reporter: thakur found ranbaxy's drugs for illnesses like aids, heart problems and infections had no proof they were effective. his findings were presented to ranbaxy executives in 2005, but he says nothing was done. >> i was dumbfounded. i had worked in this industry for 11 years, at that point in time, and never seen such callous behavior. >> reporter: he points to an incident where his young son was prescribed a ranbaxy antibiotic for a fever. >> he kept getting worse. we got anothe

you don't know. >> thakur reported his findings to the fda in 2005.vestigation found ranbakyranbak y ranbaky had a consistent factor. there were over 1,600 data factors. they were found to be unsafe to use and sell. >>. >> vince fabiano is a former ranbaxy president. >> let's say you're using a cancer drug. your cancer progresses. is it because of the drug or the disease process? >> no one knows. in many cases it would not be detected. >> in 2008 when ranbaxy came under new ownership. they were band from selling but they continued to sell in the u.s. from other indian facilities. then in 200111 while one arm was investigating ranbaxy for serious criminal violations another was approving the company for the exclusive rights to make the generic version of one of the most popular pharmaceuticals of all time. lipitor, a decision by the fda that reportedly earned the company $600 million in the first six months. david nelson led a congressional investigation into ranbaxy. >> there was behavior treatment that was suggestive of regulators that at best didn't

. >> in 2004, the ranbaxy executive dinesh thakur was asked to investigate fraud, and he uncovered disturbingions about the data to prove the effectiveness of the ranbaxy drug. >> we started get intog the files and lo and behold, we find none of it exists in the first place. >> can -- what does that mean? >> it means they have gotten approvals from the fda based on data that was fraudulent. >> there are -- there was no proof they were effective. the findings were presented to the ranbaxyexecutives in 2005, but nothing was done. >> i was dumbfounded. i have worked in this industry 12 years, and i have never seen such calous behavior. >> his young son was prescribed a ranbaxy antibiotic for a fever. >> he kept getting worse. so we got another company's formulation, and the fever went away. >> you are giving your own baby a drug that you find out after the fact, doesn't work. maybe because ... >> yeah. >> because there was nothing in it that was designed to work? >> whoo. >> and ranbaxy did provide this statement. ranbaxy remains fully committed to upholding the highest standards that patients,